Improving Postsurgical Outcomes in Crohn’s Disease

Guest: Elisa K. Boden, MD For patients with Crohn’s disease who require surgery, a variety of risk factors are involved in postoperative recovery and disease control. Learn how prehabilitation programs and lifestyle modifications can reduce complications during and after surgery with Dr. Elisa Boden, an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.

Guest: Sara Horst, MD, MPH, FACG While inflammatory bowel disease (IBD) does not typically cause significant problems in pregnancy, it’s still essential to discuss potential impacts with patients and monitor them closely. Dr. Sara Horst, a Professor of Medicine at Vanderbilt University Medical Center, joins GI Insights to discuss important considerations for pregnant patients with IBD.

Guest: Shalini Prasad, PhD Guest: Sriram Muthukumar, PhD Host: Charles Turck, PharmD, BCPS, BCCCP With the constant ups and downs of inflammatory bowel disease (IBD), consistent monitoring can help provide patient-centric care. Dr. Shalini Prasad and Dr. Sriram Muthukumar, co-founders of EnLiSense, join GI Insights to discuss the wearable device they developed to track inflammation markers in IBD patients. Dr. Prasad is the Head of the Department of Bioengineering at the University of Texas at Dallas, and Dr. Muthukumar is the CEO of EnLiSense.

Guest: Elisa K. Boden, MD For many patients with Crohn’s disease, surgery is necessary due to complications like strictures and fistulas. Dr. Elisa Boden explores risk factors and potential complications, which she spoke about at the 2025 Crohn’s and Colitis Congress. Dr. Boden is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Chey, MD Recent changes to the American College of Gastroenterology’s guidelines on H. pylori treatment provide recommendations for antibiotic susceptibility and optimal patient management. Dr. Peter Buch sits down with the lead author of these guidelines, Dr. William Chey, to learn more about implications for clinical practice. Dr. Chey is the Chief of the Division of Gastroenterology and Hepatology, the H. Marvin Pollard Professor of Gastroenterology, and a Professor of Nutrition Sciences at the University of Michigan.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Vivek Kaul, MD The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gastric cancers. To learn more about when to use each approach, Dr. Peter Buch sits down with guideline co-author Dr. Vivek Kaul. Dr. Kaul is also the Segal-Watson Professor of Medicine at the University of Rochester Medical Center in New York.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD With so many therapeutic options for Crohn’s disease and ulcerative colitis, it can be challenging to determine which one best matches your patient’s needs and preferences. Onset of action, risk of infections, disease location, and therapeutic goals are all key factors in the decision-making process. To learn more about these considerations, Dr. Peter Buch sits down with Dr. David Hudesman and explores the current therapeutic landscape for inflammatory bowel disease.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD Patients with inflammatory bowel disease (IBD) can experience a variety of extraintestinal manifestations (EIMs), including joint and eye pain and skin rashes. Dr. Peter Buch sits down with Dr. David Hudesman to discuss the impacts of these EIMs and explore best practices for patient management. Dr. Hudesman is a Professor of Medicine at NYU Grossman School of Medicine and Co-Director of NYU Langone’s Inflammatory Bowel Disease Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sun-Ho Lee, MD, PhD Recent research explored the development, validation, and implications of the GEM integrative risk score (GEM-IRS). To learn how this innovative model helps predict the future risk of Crohn’s Disease in healthy first-degree relatives, Dr. Charles Turck speaks with Dr. Sun-Ho Lee, Assistant Professor and clinician scientist at the Inflammatory Bowel Disease Centre at Mount Sinai Hospital in Toronto, Canada.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Phil Ayers, PharmD, BCNSP, FMSHP, FASHP Though 100% soybean oil was once the standard for lipid emulsions in parenteral nutrition, mixed lipid emulsions have become more popular over the last decade. But there are a variety of patient-specific factors to consider before determining which type of lipid emulsion is appropriate. Dr. Charles Turck sits down with Dr. Phil Ayers to compare the available options and recommend strategies for selecting and monitoring patients. Dr. Ayers is a Clinical Associate Professor at the University of Mississippi School of Pharmacy and the Chief of Clinical Pharmacy Services in the Department of Pharmacy at Baptist Medical Center in Jackson.